<DOC>
	<DOCNO>NCT02669706</DOCNO>
	<brief_summary>The main objective study assess safety administer intravenous ( IV ) pentamidine Pneumocystis jirovecii pneumonia ( PJP ) prophylaxis adult inpatient hematologic malignancy stem cell transplant recipient . There also assessment patient satisfaction associate intravenous pentamidine PJP prophylactic therapy .</brief_summary>
	<brief_title>Intravenous Pentamidine Pneumocystis Jirovecii Pneumonia</brief_title>
	<detailed_description>This study prospective , single arm study assess safety IV pentamidine PJP prophylaxis . Patient satisfaction associate IV pentamidine also assess use survey adapt validated Treatment Satisfaction Questionnaire Medication ( version 1.4 ) . Adult patient hematologic malignancy receive receive stem-cell transplant University Illinois Hospitals Clinics indication PJP prophylaxis therapy . They receive intravenous pentamidine plan admission chemotherapy indication and/or due receive pentamidine prophylaxis . These patient outline inclusion criterion . Patients may may receive aerosolized IV pentamidine prior inclusion study . Eligible patient receive IV pentamidine hospital admission . Patients routinely monitor nursing staff infusion . Nursing staff monitor systolic diastolic blood pressure baseline one hour post infusion . Patients also monitor nausea/vomiting . Patients receive IV pentamidine anti-emetics available call use event become nauseous . Data collect type , grade , incidence adverse effect research personnel .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Adults ( 18 year old ) Hematologic malignancy diagnosis stemcell transplant recipient Eligible PJP prophylaxis therapy time enrollment per institutional guideline compliance NCCN guideline . These patient include : Acute myeloid leukemia patient receive induction consolidation ( first line relapsed/refractory ) Acute lymphoid leukemia patient receive HyperCVAD/R ( cyclophosphamide , vincristine , doxorubicin , dexamethasone , methotrexate , cytarabine , rituximab ) Lymphoma patient receive ICE ( ifosfamide , carboplatin , etoposide ) , DAREPOCH ( doseadjusted rituximab , etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin ) , inpatient lymphoma regimens Patients receive inpatient chemotherapy regimen give monthly basis Patients receive allogeneic stem cell transplant Have give inform consent May previously receive inhaled IV pentamidine Pregnancy Prisoners Patients document allergy hypersensitivity pentamidine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>